SUBSCRIBE
SUBSCRIBE
News   Drug Development

Bristol-Myers Squibb Company Compound Potent Against Hepatitis C

April 22, 2010 | 
1 min read

Reuters -- An experimental Bristol-Myers Squibb (BMY.N) compound called BMS-790052 is proving to be the most potent yet at treating hepatitis C, an infection poorly treated with existing drugs, company researchers said on Wednesday.

Clinical research Phase I Phase III
Bristol Myers Squibb Company
MORE ON THIS TOPIC
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Influenza
Moderna’s Promised mRNA Flu Vaccine Bests Current Standard Shot
June 30, 2025
 · 
2 min read
 · 
Tristan Manalac
Composite collage picture image of man slide down arrow recession statistics data weird freak bizarre unusual fantasy billboard comics.
MASH
Altimmune Nosedives on Mixed Mid-Stage MASH Data for GLP-1/Glucagon Drug
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Profile view, and Mental Illness
Depression
Alto Digs Into Exploratory Outcomes as Depression Drug Misses Phase II Endpoint
June 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Artwork magazine collage picture of serious confident lady looking big enlargement glass isolated drawing background.
Immunology and inflammation
Nektar Declares Phase IIb Eczema Win for Rezpeg—But Analysts Unconvinced
June 25, 2025
 · 
3 min read
 · 
Tristan Manalac